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OPEN
Prostasin may contribute to chemoresistance, repress
cancer cells in ovarian cancer, and is involved in the
signaling pathways of CASP/PAK2-p34/actin
B-x Yan*,1,2,5, J-x Ma1,3,5, J Zhang2,4, Y Guo1, MD Mueller1, SC Remick1 and JJ Yu1
Ovarian cancer is the deadliest of gynecologic cancers, largely due to the development of drug resistance in chemotherapy.
Prostasin may have an essential role in the oncogenesis. In this study, we show that prostasin is decreased in an ovarian cancer
drug-resistant cell line and in ovarian cancer patients with high levels of excision repair cross-complementing 1, a marker for
chemoresistance. Our cell cultural model investigation demonstrates prostasin has important roles in the development of drug
resistance and cancer cell survival. Forced overexpression of prostasin in ovarian cancer cells greatly induces cell death
(resulting in 99% cell death in a drug-resistant cell line and 100% cell death in other tested cell lines). In addition, the surviving
cells grow at a much lower rate compared with non-overexpressed cells. In vivo studies indicate that forced overexpression of
prostasin in drug-resistant cells greatly inhibits the growth of tumors and may partially reverse drug resistance.
Our investigation of the molecular mechanisms suggests that prostasin may repress cancer cells and/or contribute to
chemoresistance by modulating the CASP/P21-activated protein kinase (PAK2)-p34 pathway, and thereafter PAK2-p34/JNK/c-jun
and PAK2-p34/mlck/actin signaling pathways. Thus, we introduce prostain as a potential target for treating/repressing some
ovarian tumors and have begun to identify their relevant molecular targets in specific signaling pathways.
Cell Death and Disease (2014) 5, e995; doi:10.1038/cddis.2013.523; published online 16 January 2014
Subject Category: Cancer
It is estimated that about 22 000 new cases of ovarian cancer
and 15 000 deaths from this malignancy will occur in the
United States in 2013.1 Chemotherapy after surging is the
standard treatment for ovarian cancer, which may result in
complete clinical remission in up to 75% of cases.2 However,
a majority of responders will relapse within 18–28 months and
only 20–40% of women will survive beyond 5 years.3–5
Ovarian cancer is the deadliest of gynecologic cancers,
largely due to the development of drug resistance in
chemotherapy and late-stage diagnosis.
Prostasin, also known as PRSS8 (protease serine 8), is a
trypsin-like serine peptidase expressed in epithelial cells, with
the highest expression in the normal prostate gland and
seminal fluid and lesser amount in various tissues.6,7 The
expression of prostasin has been shown to malexpress in
ovarian, prostate, breast, and gastric cancers8–11 and to be a
potential biomarker for ovarian cancer early detection alone or
in combination with CA125.9,12,13 Prostasin has been sug-
gested to inhibit cancer cell proliferation and invasion.14
Prostasin is also termed channel-activating protease 1, which
is implicated in the regulation of sodium and fluid levels via
proteolysis of the epithelial sodium channel, and thus has
important functions in blood pressure being a target for
regulating hypertension.15–17 In addition, prostasin has been
found to have important roles in the epidermal barrier function,
skin phenotypes, and embryonic viability.18,19 Thus, prostasin
is implicated in a wide spectrum of physiological and
pathophysiological conditions.
P21-activated protein kinase (PAK) 2 is a serine/threo-
ninekinase, which has critical roles in various cytoskeletal
functions, such as cell motility and membrane blebbing during
apoptosis.20,21 Full-length PAK2 can be activated either by
the small GTPases CDC42 and Rac or CASPs, which
stimulates cell survival or induction of cell death in response
to many apoptotic stimuli.21 PAK2-p34 is a constitutively
active 34-kDa PAK2 C-terminal kinase fragment cleaved by
several CASPs members.22 Recombinant expression of PAK-
2p34 induced morphological changes characteristic of apop-
totic cell death in a variety of cell lines and induced apoptotic
cell death.23,24 In addition, accumulation of PAK2-p34 by
ubiquitin inhibits degradation results in a dramatic increase in
cell death.25 Therefore, PAK2-p34 is involved in cellular death
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regulation and execution of programmed cell death, and
caspase activation stimulated by apoptotic stimuli appears to
turn the antiapoptotic activity of PAK2 into a proapoptotic
activity of PAK2-p34. Aberrant activity/level of PAK2 or
PAK2-p34 has been linked with human cancer, Alzheimer’s,
and Parkinson’s disease.23
In this work, we focus on the functions of prostasin in
chemoresistance and tumor repression. Our investigations
revealed that prostasin has critical roles in chemoresistant
development and cell survival. Forced overexpression of
prostasin greatly reduces cancer cell survival, and may
partially reverse chemoresistance. Therefore, prostasin may
be a potential target for treating some ovarian tumors,
including chemoresistant tumors. Investigations of the signal-
ing pathways suggest that prostasin may repress cancer cells
and/or contribute to chemoresistance by modulating the
CASP/PAK2-p34 and thereafter PAK2-p34/JNK/c-jun and
PAK2-p34/mlck/actin signaling pathways.
Results
Prostasin expression is decreased in ovarian cancer
patients with high expression of excision repair
cross-complementing 1 (ERCC1), a marker for
chemoresistance in ovarian cancer. ERCC1, the essential
nucleotide excision repair component, is a biomarker for
chemoresistance and a target to overcome chemoresistance
in cancer therapy.26–30 We proposed that prostasin may
have role in chemoresistance because it is malexpressed in
various types of cancers.8–11 To investigate the possible
association, we examined prostasin expression in ovarian
tumor samples with known ERCC1 expression, representing
chemoresistant phenotype.31 Real-time quantitative PCR data
showed that prostasin expression was significantly lower in
tumor samples from ERCC1-high group (n¼ 18), compared
with ERCC1-low group (n¼ 31), and that prostasin mRNA is
greatly reduced in potentially chemoresistant tumors
compared with chemosensitive tumors (Figure 1a, Po0.01).
We examined prostasin protein level in these tumor samples
using immunohistochemistry. The data show that prostasin
protein is decreased in chemoresistant/ERCC1-high tumors
compared with chemosensitive/ERCC1-low tumors (Figure 1b),
which is consistent with prostasin mRNA level. These results
demonstrated that prostasin is decreased in ovarian tumors
with high ERCC1 expression, the chemoresistant phenotype.
Therefore, prostasin may have an important role in
chemoresistance in ovarian cancer.
Prostasin is decreased, has key roles in chemoresis-
tance and cell survivals in ovarian cancer cells. To study
the function of prostasin in chemoresistance, we examined
prostasin expression in ovarian cancer paclitaxel-resistant
cell line O432-RP (it also cross-resistant to cisplatin), a cell
line we generated previously from ovarian cancer cell
Ovca432 (O432),32 and performed the functional investiga-
tions. Western blot analysis showed that prostasin is
deceased in drug-resistant O432-RP cell line, compared
with the parental-sensitive O432 cell line (Figure 2a),
suggesting prostasin may be involved in acquired chemore-
sistance in ovarian cancer cells. We then examined
chemoresistant phenotype after knockdown prostasin
in sensitive O432 cell and overexpression of prostasin in
resistant cell O432-RP. siRNA knockdown prostasin in
O432 cells obtained greatly reduced prostasin cells (O432-
pro-D: Figure 2b) compared with the control cells. These
cells were treated with paclitaxel at several doses and drug
sensitivity was assessed by cell survival assays. We
observed that O432-pro-D cells have a higher survival rate
compared with O432 cells, which transfected with no-
targeting siRNA or reagent (Figure 2c). The data demon-
strated that O432-pro-D cells are more resistant to paclitaxel
treatment compared with the control cells, suggesting that
downregulation of prostasin alone may result in increasing
chemoresistance. In contrast, we overexpressed prostasin
by transfecting prostasin cDNA containing vector into
O432-RP cells. To our surprise, we observed that forced
Figure 1 Reduced prostasin expression in patients with high expression of ERCC1, a marker for chemoresistance in ovarian cancer. (a) Prostasin mRNA levels were
compared in tumors with high ERCC1 levels (ERCC1 average¼ 1.54, n¼ 18) representing the chemoresistant phenotype, and in tumors with low ERCC1 levels (ERCC1
average¼ 0.44, n¼ 31) representing the chemosensitive phenotype26,27 by real-time qPCR analysis. Relative levels of prostasin in chemoresistant versus chemosensitive
tumors are shown, respectively. **Po0.01. Mean±s.d. are given, and P values were calculated using the two-sided Student’s t-test. (b) Expression of prostasin by
fluorescent immunohistochemistry in (patient-derived) ovarian tumor samples. Prostasin is decreased in ovarian ERCC1-high tumors compared with the ERCC1-low tumors
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overexpression of prostasin resulted in inducing cell death
dramatically, with more than 99.99% cells dead after
successful transfection (Figure 2d). Less than 0.01% of the
surviving cells (named O432-RP-pro-O), which expressed
higher prostasin (Figure 2e), were found to have a very low
growth rate compared with the control cells O432-RP and
O432-RP-C (transfected with empty vector; Figure 2f). These
three cell sub-lines were then treated with paclitaxel at
several doses and were assessed for the drug sensitivity by
cell survival assays. The survival rate of O432-RP-pro-O was
dramatically reduced compared with the control cells
(Figure 2g), suggesting that chemoresistance may be
reversed. We also tried to overexpress prostasin in other
ovarian cancer cell lines, such as Uci101, OVCAR-3, and
Caov-3. As seen in the O432-RP cell line, cell death was
greatly induced upon prostasin overexpression. However, we
did not detect any surviving cells in these cell lines after
prostasin cDNA was successfully transfected, which was
assessed by geneticin selection and control transfections
(Figure 2e). These results indicate that forced overexpres-
sion of prostasin in ovarian cancer cells dramatically induces
cell death – 100% in some cell lines and more than 99.99%
in the other cell line – and represses the cell growth of
surviving cells, and may partially reverse chemoresistance.
These functional studies indicate prostasin may have critical
roles in cell survival and chemoresistance in the studied cell
models.
Overexpression of prostasin represses chemoresistant
tumors. We extended our in vitro finding to a mouse tumor
model to explore the potential of prostasin as a therapeutic
target for treating/repressing some ovarian tumors. The
tumor cells of O432-RP-pro-O and O432-RP-C were
implanted into each flank of mice. These tumor-bearing
animals were treated with paclitaxel or vehicle PBS when the
tumor volume reaches about 100 mm3 (the tumor volume of
O432-RP-C is about 100 mm3at the time of treatment;
however, the volume of O432-RP-pro-O tumor is only about
50 mm3 because of low growth rate of cells). At the end of
treatment, we compared the tumor volumes of O432-RP-C
and O432-RP-pro-O in the presence and absence of
paclitaxel, respectively. In the absence of paclitaxel treat-
ment (e.g., just vehicle PBS), we observed that O432-RP-
pro-O tumors were significantly smaller compared with that of
O432-RP-C control tumors (Po0.01, Figures 3a and b). We
believe this is probably due to the low growth rate of this cell
line, which overexpressed prostasin. In addition, we
observed that the O432-RP-pro-O tumors became further
smaller when treated with paclitaxel (Po0.001, Figures 3a
and b), and paclitaxel-treated O432-RP-pro-O tumors were
slightly smaller than PBS-treated O432-RP-pro-O tumors
(Po0.1, Figures 3a and b). The data suggest that restoration
of prostasin in chemoresistant cells inhibits growth of these
tumors and may partially reverse chemoresistance, which is
consistent with our in vitro findings.
Prostasin regulates a network involving CASP/PAK2-p34
and thereafter mlck/actin, and JNK/c-jun pathways in
ovarian cancer cells. To uncover the signaling pathways
for prostasin in cell survival and chemoresistance, we
compared the expression profile of O432-RP-pro-O and
O432-RP-C cells using PCR arrays analysis.
b-Actin was found to be decreased in O432-RP cells
compared with O432 cells in our study (we initially used
b-actin as a loading control for western blot analysis; however,
we found b-actin is not consistant when we used GAPDH as
loading control for equal loading of samples (Figure 4a)). With
the previous finding that b-actin expression changed in breast
cancer drug resistance cells, this prompted us to hypothesize
that b-actin and cytoskeletal genes may be involved in the
prostasin-directed chemoresistance development as actin
gene is believed to be a central player of cell shape and
movement and a key component of cytoskeleton.33 We
examined gene expression of cytoskeleton pathway using
PCR array in these cells. The PCR array data showed that
PAK and mlck increased, and b-actin decreased in O432-RP-
pro-O cells, compared with control O432-RP-C cells
(Figure 4b). Western blot analysis further demonstrated that
protein levels of mlck and b-actin changed, which were
consistent with mRNA levels (Figure 4a). However, we did not
see significant difference for PAK proteins. Instead, we
observed that PAK2-p34, a 34KD C-terminal fragment of
PAK2, which is cleaved by CASPs,34,35 is increased in O432-
RP-pro-O cells. PAK2-p34 has been shown to regulate JNK
expression during apoptosis,20 so we examined JNK and
thereafter target c-jun expression. The western blot analysis
showed that JNK and c-Jun both increased in O432-RP-pro-O
cells. The data suggested that prostasin regulates PAK2-p34
and thereafter JNK and c-jun signaling in these cells. In
addition, mlck has been shown to be a downstream target of
PAK2/PAK2-p34, and upstream target of actin. Thus, PAK2-
p34 seems to be an important mediator of prostasin in these
cells and appears to regulate JNK/c-jun and mlck/act sub-
pathways.
To explore the upstream targets of PAK2-p34, we
examined expression of several CASP genes, as PAK2-p34
is specifically cleaved by CASPs.34,35 Interestingly, several
CASPs were found increased in O432-RP-pro-O cells
compared with O432-RP-C cells (Figures 4c and d). To
confirm that PAK2-p34 is cleaved by CASPs, we blocked
CASPs activity using CASPs inhibitors. We observed that the
cleavage was blocked (PAK2-p34 decrease or disappear) as
early as 12 h after incubating the cell with CASPs inhibitor
(Figure 4e). Thus, CASPs are upstream targets of PAK2-p34
and downstream target of prostasin in our experimental
system. We tried to identify the upstream signaling of CASPs
in these cells, but were unsuccessful. We also checked the
expression level of these prostasin downstream targets in
prostasin knockdown cells O432-pro-D compared with the
control, and a reverse pattern was revealed (Figure 4f). The
data suggest that prostasin may affect chemoresistance
and/or cell survival through regulating the CASPs/PAK2-p34
axis and thereafter JNK/c-jun and mlck/actin signaling
pathways (Figure 5).
Discussion
Dramatic advances have been made in understanding
cancer’s basic mechanisms during recent decades. Despite
these advances, ovarian cancer is still a deadly disease with a
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less than 50% 5-year survival rate.1 Antitumor drug resistance
or non-response to chemotherapy is one of the major
challenges to successful treatment of ovarian cancer. In this
study, we show that prostasin expression is significantly
decreased in both ovarian cancer chemoresistant cells and in
tumor tissues of high ERCC1-expressing ovarian cancer
patients. ERCC1 has been well-described as a potential
biomarker for drug resistance.26–29 Prostasin appears to have
an important role in chemoresistance. The functional investi-
gations demonstrate that forced overexpression of prostasin
Prostasin represses ovarian tumors
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in ovarian cancer cells induces more than 99.99% cell death
and represses the cell growth of surviving cells, and may
partially reverse chemoresistance. This indicates that prostasin
may have very strong power in repressing cancer cells and
have roles in chemoresistance. Thus, may be a target for
treating/repressing some ovarian tumors in gene therapy.
Prostasin may have an important role in the development of
various types of cancers, including ovarian, prostate, breast,
and gastric cancers, and expression of prostasin has been
shown to be changed in these cancer patients.8–11 In addition,
restoration of prostasin in prostate cancer cells results in the
inhibition of cell proliferation and invasion.14 Therefore,
prostasin is believed to be a tumor suppressor in prostate
and breast cancers. For ovarian cancer, the role of prostasin is
complex. It is overexpressed in ovarian cancer patients
suggesting it is an oncogene.9 Our findings show that
prostasin is decreased in potentially chemoresistant ovarian
cancer patients and chemoresistant cell line, and forced
overexpression of prostasin in ovarian cancer cells greatly
induces cells death, which behaves like a tumor suppressor.
Prostasin is overexpressed in ovarian cancer patients with all
stages. However, the levels change significantly from early to
late stages. Prostasin increases and reaches a peak level at
stage II and III and then decreases sharply at stage IV (the
level is still slightly higher than in normal tissue).9 Therefore,
decreased prostasin (advanced stage compared with early
stage patients) may be required for advanced ovarian cancer
cells, or prostasin has different roles in different stage cancer
cells. Prostasin is a glycosylphosphatidylinositol-anchored
membrane protein as well as a secreted protein from epithelial
cells, where it is bound to the cell surface, secreted, or both.10
Studies showed that the membrane-anchored form of
prostasin has important roles in tumor or invasion suppression
of prostate or breast cancers, but not the secreted or
recombinant prostasin.10 Our finding is consistent with these
observations, which demonstrate that forced overexpression
of prostasin inhibits cancer cells growth, but the recombinant
prostasin has no effect on cell growth or death in ovarian
cancer cells (data not shown). Therefore, membrane-
anchored prostasin has critical roles in cell survival and/or
chemoresistance, and overexpression of prostasin triggers
cell death in some ovarian cancer cells. We propose that
prostasin is a potential target for treating some ovarian tumors
in gene therapy, which overexpress prostasin in cells, but not
by infusion of secreted/recombinant prostasin. Overexpres-
sion of prostasin can be done either by traditional transgene
methods or newly identified gene-regulation mechanisms to
enhance gene expression through transfection of promoter-
associated siRNAs.36
The signaling pathways that we investigated show that
prostasin controls the downstream axis of CASPs/PAK2-p34,
and thereafter mlck/actin and JNK/c-jun sub-signalings, in
ovarian cancer cells. The finding suggests a new mechanism
by which prostasin induces cell death and/or contribute to
chemoresistance through regulating these pathways
(Figure 5). The CASPs are believed to be the core effectors
of apoptosis.37 PAK2-p34 has been shown to induce cell
death may be by increasing signal of JNK and regulating
cytoskeletal dynamics of mlck pathways.20 All these genes
and signaling pathways33,38,39 have essential roles in apop-
tosis and transcription. Therefore, prostasin may contribute to
chemoresistance and repress cancer cells through these
mechanisms. Study showed that overexpression of PAK2-
p34 in cancer cells induced apoptosis and cell death.20 We
also observed that forced overexpression of PAK2-p34 in
chemoresistant cell O432-RP greatly inhibited cell survival
(Supplementary Figure 1). We propose that PAK2-p34 is a
key executer of prostasin, and prostasin induces cancer cell
death and/or contributes to chemoresistance by regulating
these signaling pathways in our experimental system. Further
functional studies should build the direct link between
prostasin and these pathways. Our pathway analysis is
focused on the apoptosis. Surely, the functions of prostasin
in cell death and chemoresistance may involve in other
pathways, such as cell cycle or stem cell development, and
future study may focus on these topics.
PAK2 has been shown to contribute to chemoresistance in
breast cancer cells by decreasing levels of active caspase-3
and thereafter PAK2-p34 (PAK2 and PAK2-p34 have oppos-
ing role in cell apoptosis). b-Actin was also found to be altered
in these cells.36 We proposed that alteration of b-actin should
result from CASP/PAK2 (PAK2-p34)/mlck regulation, as mlck
is one main target of PAK2-p34.15 Together with our findings,
the data suggest CASP/PAK2-p34 and sub-pathways there-
after may have an important role in chemoresistance in
different cancer types (Supplementary Figure 2). In addition,
changes in b-actin have been shown both in breast cancer
drug-resistant (cisplatin and paclitaxel) cells36 and our ovarian
cancer drug-resistant cells. Involvement of b-actin in drug
resistance in different types of cancer precludes it as an
internal control in the future study.
In summary, our study points to prostasin as a potential
target for treatment/repress of some ovarian cancers, including
chemoresistant tumors. The pathway and mechanism
Figure 2 Prostasin has important roles in chemoresistance and cell death in cell culture model. (a) Prostasin decreased in paclitaxel-resistance cancer cell line. O432:
ovarian cancer cell line Ovca432 (sensitive to paclitaxel); O432-RP: paclitaxel resistance cell line generated from Ovca432. The prostasin protein levels in O432 and O432-RP
cells are shown in immunoblots with specific antibodies. (b) Prostasin siRNAs transfection reduced prostasin. O432-pro-D cells (transfected with prostasin siRNA) express
lower prostasin, compared with control cells of O432 (transfected with reagent only) and O432-Cs (transfected with no-targeting siRNA). The prostasin protein levels are
shown in immunoblots with specific antibodies. (c) Downregulation of prostasin in O432 cells resulted in increase of chemoresistant activity. Cells were treated with paclitaxel
at different concentrations for 24 h (starting 48 h after siRNAs transfection) and cultured with normal medium for an additional 7 to 10 days before cell survival was assayed.
Relative cell survival rates of each cell line are shown. (d) Overexpression of prostasin greatly induces cell death in ovarian cancer cells. The cell survival rates are shown after
forced overexpression of prostasin in several cell lines from day-0 to day-8, respectively. (e) Prostasin cDNA transfection resulted in overexpression of prostasin in
chemoresistant O432-RP cells. O432-RP-pro-O cells (transfected with prostasin cDNA) express higher prostasin compared with control cells O432-RP and O432-RP-C
(transfected with control vector). The prostasin protein levels are shown in immunoblots with specific antibodies. (f) Forced overexpression of prostasin represses growth of
chemoresistant cells. Relative cell growth rates are shown for O432-RP-pro-O and control cells O432-RP and O432-RP-C. (g) Forced overexpression of prostasin in O432-RP
cells re-sensitizes chemoresistant cells. Cells were plated at about 10–20% confluence and treated with paclitaxel at different concentrations for 24 h, cultured with normal
medium for additional 7 to 10 days, then assayed for cell survival. Relative survival rates of cell lines are shown
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findings suggest prostasin may regulate cancer cell survival
and/or chemoresistance by controlling CASPs/PAK2-p34 and
thereafter signaling through apoptosis mechanisms.
Meterials and Methods
Human samples and ethics statement. Frozen GOG (Gynecologic
Oncology Group) samples from ovarian cancer patients were obtained from the
Cooperative Human Tissue Network, Pediatric Division (Children’s Hospital,
Columbus, Ohio). All patient identifiers of these samples had been stripped of
before shipping to ensure that the presented molecular laboratory data cannot be
linked with any subject in this study. The tumor specimens were collected at
primary surgery, fresh frozen in liquid nitrogen, and stored at  80 1C until RNA/
DNA extraction. All samples were evaluated by pathologists.
Cell lines, cell culture and generation of drug-resistance
sub-line. Cell lines, cell culture and generation of drug-resistance sub-line
are described as previously.32 All cell lines were propagated as an adherent
monolayer in MEM (Invitrogen, Life Technologies, Inc., Carlsbad, CA, USA) at
37 1C in a humidified atmosphere of 5% CO2 supplemented with 10% heat
inactivated FBS, 100 mg/ml penicillin, and 100 mg/ml streptomycin. Human
ovarian cancer cell lines of Ovca432 and Uci101were provided by Dr. Liu T from
the Chinese Academy of Sciences. OVCAR-3 and Caov-3 were purchased from
ATCC (Manassas, VA, USA). The Ovca432-RP drug-resistance sub-cell line
was generated from Ovca432 cells with paclitaxel (Sigma-Aldrich, Inc.,
St. Louis, MO, USA) treatment at increasing concentrations for several cycles
(each cycle including 24-h exposure to the drug, and subsequent recovery
culture with normal medium for about 10 days) until cells were found resistant to
treatment.
RNA extraction and cDNA generation. Total RNA from tumors of ovarian
cancer patients was partially purified by hot phenol/chloroform extraction as previously
reported.40 Through reverse transcription, using the Super Script Preamplification
System (Life Technologies, Inc.), cDNA was generated with oligo-dT primers from
5mg of total RNA per sample (Life Technologies, Inc.). Total RNA was extracted from
cells using Trizol. The cDNA was synthesized using Taqman Reverse Transcription
(PE Applied Biosystems, Foster City, CA, USA) from 1mg of total RNA. cDNAs were
used for the gene expression profiling.
Real-time reverse transcription quantitative-PCR. Real-time quan-
titative PCR was performed with an ABI PRISM 7900 or 7500 instrument (PE
Applied Biosystems) according to the manufacturer’s instructions as previously
described.32 PCR cycling conditions were set as follows: 50 1C, 2 min; 95 1C,
10 min; and 40 cycles for the melting (95 1C, 15 s) and annealing/extension (60 1C
for 1 min) steps. qPCR reactions for each template were carried out in duplicate or
triplicate in 96-well plates. Comparative Ct (PE Applied Biosystems) determined
relative expression in each sample using 18S or GAPDH as endogenous controls.
Western blot. Western blot analysis was performed as previously described.32
Briefly, cells were rinsed twice with PBS and total proteins were solubilized in lysis
buffer (150 mM sodium chloride; 50 mM Tris hydrochloride, pH 7.5;1% glycerol;
1% Non-idetp-40 substitute solution). Equal amounts of proteins were loaded and
separated by SDS-polyacrylamide gel electrophoresis. Proteins were transferred
to a polyvinylidene difluoride membrane, blocked by 5% skim milk, and probed
with the specific (primary) antibodies, followed by treatment with secondary
antibody conjugated to horseradish peroxidase (1 : 5000). Proteins were visualized
by (enhanced) chemiluminescence detection (Pierce Biotechnology, Rockford,
IL, USA) and exposure to X-ray film. b-Actin or Gapdh proteins were detected
by normal chemiluminescence detection (Pierce Biotechnology) and exposed to
less-sensitive X-ray film, which may result in a relatively weaker signal. All antibodies
used in this study were obtained from Abnova (Taipei, Taiwan) or Abcam
(Cambridge, MA, USA).
siRNA and cDNA transfection. O432 cells were transfected with prostasin
siRNA duplexes (Ambion, Austin, TX, USA) and O432-RP cells with prostasin or
PAK2-p34 cDNA-containing vectors (cDNAs were amplified by reverse transcrip-
tion PCR and then cloned into a pCI-neo vector) using Lipofectamine 2000
(Invitrogen) according the manufacturer’s instructions. For siRNA experiments,
mock transfections and no-targeting siRNA were used as negative controls. Cells
were treated for 72 h to allow for maximum knockdown, after which they were
lysed for western blot analysis, RNA preparation or other assays. For cDNA
transfection, a pCI-neo vector was used as a negative control. Geniticin was used
to select stably expressing cells.
Cell survival assay. Cell survival assay was performed as previously
described.32 Cells were counted and plated in culture dishes at about 10–20%
confluence on the day before treatment. Paclitaxel or control PBS was added for
about 20 h and removed, then the cells were cultured with normal medium for
recovery and continuous propagation for 10–14 days. To quantify final cell
numbers, cells were stained with 0.25% crystal violet/20% ethanol and counted, or
Figure 3 Forced restoration of prostasin represses and re-sensitizes
chemoresistant tumors. (a) Overexpression of prostasin represses and re-sensitizes
chemoresistant tumors. O432-RP-pro-O cells (stably transfected with prostasin
cDNA) or control cells O432-RP-C (stably transfected with control pCI-neo vector)
were injected into the left and right flanks of mice, respectively. The animals were
treated with paclitaxel (15 mg/kg/week) or control vehicle PBS for 2 weeks after the
tumors reached about 100 or 50 mm3. Tumor volumes before and after treatment
are shown. O432-RP-psp-O-c and O432-RP-psp-O-t: PBS- and paclitaxel-treated
O432-RP-psp-O tumors; O432-RP-C-c and O432-RP-C-t: PBS- and paclitaxel-
treated O432-RP-C tumors. n¼ 6 per group, **Po0.01. Mean±s.d. are given,
and the P-values were calculated using the two-sided Student’s t-test. (b) Tumors in
mice before and after treatments. Scale bar¼ 5 mm
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the proliferation rate was measured using a Cell Proliferation Assay kit (Promega,
Madison, WI, USA) according to manufacturer’s instructions. Briefly, MTS/PMS
solution (at final concentrations of 333mg/ml MTS and 25mM PMS) was added to
each well and cells were incubated for 2–3 h at 37 1C. The absorbance was
determined at 490 nm using a 96-well plate ELISA reader. Culture medium was
used as background control. The experiments were repeated at least three times.
Immunofluorescence. The tumor sections were deparaffinized in
Histo Clear II (Electron Microscopy Sciences, Hatfield, PA, USA), hydrated in
gradient alcohol (passed through gradient alcohol washes), and antigen retrieval
treated in a microwave oven for 10 min at ‘Power 20%’ in citrate buffer (0.01 M,
pH¼ 6.0,0.05% Tween-20), then cooled for 20 min. The sections were incubated with
blocking buffer (2% goat serum, 5% BSA, 0.1% cold fish skin gelatin, 0.1% Triton
Figure 4 Prostasin regulates CASPs-PAK2-p34 axis and thereafter downstream signaling. (a) Immunoblot of mlck, b-actin, PAK2-p34, JNK, C-Jun in O432-RP-pro-O
(O432-RP cells transfected with prostasin cDNA which express higher levels of prostasin) control O432-RP-C cells (O432-RP cells transfected with pCI-neo vector). Mlck,
PAK2-p34, JNK, C-Jun expressions increase and b-actin decreases in O432-RP-pro-O cells when compared with control O432-RP-C. (b) Comparison of actin, mlck, and pak1
expression between O432-RP-pro-O and control O432-RP-C cells by real-time qPCR. mRNA levels of actin decreases and mlck and pak1 increase in O432-RP-pro-O cells
compared with control O432-RP-C cells. (c) mRNA levels of CASPs detection by real-time qPCR in O432-RP-pro-O cells and control O432-RP-C cells. Several CASP
expression increase in O432-RP-pro-O cells compared with the controls. (d) Immunoblot of CASP3, 9, and 10 in O432-RP-pro-O and O432-RP-C cells. CASP3, 9, and 10
protein levels increase in O432-RP-pro-O cells compared with control O432-RP-C cells. (e) CASP inhibitors block CASP activity and thus PAK2 cleavage. PAK2-p34 protein
was examined by immunoblot after CASP inhibitors were added to the medium. PAK2-p34 was seen decreased or lost when CASPs were inhibited at several time points.
(f) Immunoblot of mlck, b-actin, PAK2-p34, JNK, C-Jun, CASP3, 9, and 10 in prostasin knockdown O432-pro-D cells and controls O432 (mock transfected with reagent only) and
O432-Cs (transfected with no-targeting siRNA). Reverse expression patterns for these genes are revealed in O432-pro-D cells and controls compared with O432-RP-pro-O
cells and controls
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X-100, 0.05% Tween-20, 0.05% sodium azide, pH 7.2) for 2 h. Thereafter, the slides
were incubated with mouse monoclonal anti-prostasin antibody (1 : 20 dilution)
overnight at 4 1C. The primary antibody was detected using anti-mouse IgG Alexa
Fluor 488 (Life Technologies, Inc.). Slides were mounted with the SlowFade Gold
AntiFade reagent with DAPI (Life Technologies, Inc.). In the negative control tissue
sections, the primary antibody was replaced by isotype-specific non-immune mouse
IgG. Immunoreactivity was visualized and photographed using a Nikon confocal
microscope (Nikon Elipse90i, Deutschland, Germany) at the appropriate wavelength.
Tumor mouse model study. We performed mouse experiments as
previously described32 and in compliance with the published guidelines of
Laboratory Animal Care (NIH Publication No. 85-23, revised 1985; http://
grants1.nih.gov/grants/olaw/references/phspol.htm) and the Care and Use of
Laboratory Animals (National Research Council, 1996). Four- to six-week-old
female BALB/cnu mice (Charles Rivers Laboratories, Wilmington, MA, USA and
Laboratory Animal Research Center, Shanghai, China) were used to generate
xenograft tumors. 1.0 107 cells were suspended in 200ml saline solution and
injected into both flanks of mice. The mice were treated with paclitaxel (15 mg/kg)
or vehicle PBS by intratumoral injection for 2 weeks when tumor volume reached
about 100 or 50 mm3. Tumor volume and mouse weight were monitored
accordingly.
CASPs inhibition experiment. CASP family inhibitor (MBL International,
Woburn, MA, USA) was added to the culture medium at 1000-fold dilution to inhibit
caspase activity. Cells were lysed after 12 and 24 h post inhibitor treatment and
subjected to western blot analysis.
Statistical analysis. Statistical analysis was conducted using Student’s t-
test. Statistical significance was defined as Po0.05. All statistical tests and
corresponding P-values were two-sided.
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